EU approves biosimilar of J&J and Merck's Remicade, WSJ says

theflyonthewall.com

The European Commission has approved a lower-priced "biosimilar" version of Johnson & Johnson (JNJ) and Merck's (MRK) Remicade treatment for rheumatoid arthritis, says the Wall Street Journal. Hospira (HSP) and Celltrion make a rival named Inflectra, added the WSJ.

Rates

View Comments (0)

Recommended for You